Oligonucleotides News and Research

RSS

Oligonucleotides are short sequences of nucleotides (RNA or DNA), typically with twenty or fewer bases. Automated synthesizers allow the synthesis of oligonucleotides up to 160 to 200 bases.

Current and future perspectives of mRNA technology

New research reports on the current and future perspectives on messenger ribonucleic acid technology, the platform on which the first successful COVID-19 vaccine was based.

8 Mar 2022

Codiak's publication highlights the ability of exoASO-STAT6 to selectively target tumor-associated macrophages

Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a new class of medicines, today announced the online publication of a new manuscript, Exosome mediated genetic reprogramming of tumor associated macrophages by exoASO-STAT6 leads to potent monotherapy anti-tumor efficacy, in the American Association for the Advancement of Science's journal, Science Advances.

18 Feb 2022

Researchers find a way to interfere with the energy pathway that promotes liver cancer spread

The World Health Organization projects that starting in 2030, over a million people will die each year from liver cancer.

4 Feb 2022

New approach using RNA therapeutic can fix protein problems in cystic fibrosis

The process of generating proteins from genes is akin to a factory, where workers follow a set of instructions that, ideally, are effective and clear.

27 Jan 2022

Single-patient pilot study shows the ability of antisense oligonucleotide to suppress mutant ALS gene

Using a short, synthetic chain of chemically modified nucleotides engineered in the RNA Therapeutics Institute at UMass Chan Medical School, Robert H. Brown Jr., DPhil, MD, Jonathan Watts, PhD, and colleagues have shown the ability to suppress mutant forms of an ALS gene known as C9ORF72 in a single-patient pilot study.

24 Dec 2021

Exploring the impact of DNA nanoswitches in RNA purification

A new study reports a tool to enable RNA purification by sequence, helping to determine the structure, chemical modifications, and interactions between different RNA molecules.

15 Dec 2021

Telomeric DNA damage response may increase susceptibility of elderly people to COVID-19

SARS-CoV-2 causes the pandemic coronavirus disease COVID-19, that is more harmful for elderly people, who show more severe symptoms and are at higher risk of hospitalization and death.

3 Dec 2021

Study involving a rat model offers potential treatment for Alexander disease

Alexander disease is a progressive and rare neurological disorder with no cure or standard course of treatment. But a new study led by researchers at the University of Wisconsin–Madison involving a rat model of the disease offers a potential treatment for the typically fatal condition.

18 Nov 2021

Nucleoside modifications suppress the potential of RNA to activate dendritic cells

A new paper shows that human TLR3, TLR7, and TLR8 receptors are activated with naturally occurring RNA, but this is eliminated once modified nucleosides such as m5C, m6A, m5U s2U, or pseudouridine are incorporated.

12 Oct 2021

Plasmonic sensing of isothermally amplified nucleic acids and single-molecule detection of SARS-CoV-2

A new study finds that plasmonic sensing of LAMP amplicons through DNA hybridization enables highly specific detection of SARS-CoV-2 RNA.

11 Oct 2021

Design of mRNA vaccines to combat COVID-19

A recent review study discusses fundamental concepts in the successful delivery of nucleic acids in therapeutics.

23 Sep 2021

The role of nanomaterials during the COVID-19 pandemic

A new review published in Rare Metals has focused on the applications of nanomaterials to fight the ongoing COVID-19 pandemic.

22 Sep 2021

Aptamers for Targeting SARS-CoV-2 Proteins

AMSBIO has further expanded its product range to help in the fight against COVID-19 with the introduction of a new range of aptamers targeting SARS-CoV-2 proteins to aid development of new kits and assays.

From AMS Biotechnology 15 Sep 2021

Researchers find a way to turn SARS-CoV-2’s virulence mechanism against itself

A recent study, currently available on the bioRxiv* preprint server, reveals that a specific region of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can be targeted by antisense oligonucleotides to potently inhibit viral replication, and consequently the development of coronavirus disease (COVID-19).

12 Sep 2021

Antisense oligonucleotides engineered to inhibit SARS-CoV-2

In a paper recently uploaded to the bioRxiv* preprint server, structure-based ASOs are developed against SARS-CoV-2, intended to bond with RNA in its structured in situ form, rather than the more rarely encountered linear section, achieving greater affinity and specificity than linear ASOs, and demonstrating inhibition of virus replication in human cells.

30 Aug 2021

Innovative therapeutic platform for blood-to-brain delivery of antisense oligonucleotide therapy

Antisense oligonucleotide (ASO) therapy has the potential to ameliorate many neurodegenerative diseases at the genetic level to suppress the production of harmful proteins or non-coding RNAs.

12 Aug 2021

Potential new treatment for mast cell cancers reduces tumor size and prevents organ infiltration

A potential new treatment for mast cell cancers reduces the number of mast cells by "mutating" the messenger RNA (mRNA) before it can deliver instructions for manufacturing the gene responsible for cell proliferation.

10 Aug 2021

Diagnosis of viral infections using micro and nanoscale technologies

In a recent study, the authors provide a review on both micro- and nanoscale technologies that advanced the diagnosis of viral diseases.

3 Aug 2021

Researchers discover titanium oxide nanoparticle that recognizes SARS-CoV-2’s non-structural protein 1

A pioneering study reports on the interaction of a tailored titanium oxide nanoparticle (NP) with the full-length SARS-CoV-2 non-structural protein 1 (nsp1). This should be of value in developing new therapeutic tools against coronaviruses that act by targeting their proteins. It could also help map the structure of activated proteins.

2 Aug 2021

Polyuridine sequence of mouse coronavirus can be targeted to prevent host cell death

A new study reports the use of a modified deoxyribonucleic acid (DNA) oligonucleotide that has a 3’ polyadenine (polyA) tail to bind to the 5’-polyU tract in the mouse coronavirus (MHV-A59). Treatment of mouse cells infected with MHV-A59 with this molecule led to a marked reduction in cell deaths.